Therapy Areas: Oncology
Enhertu recommended for EU approval in previously treated HER2 positive metastatic solid tumours
22 May 2026 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) announced on Friday that Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union as a monoth...
OSE Immunotherapeutics reports positive Phase 2 ovarian cancer trial results
22 May 2026 - French biotechnology company OSE Immunotherapeutics SA (Euronext Paris:OSE) on Friday reported positive topline results from the Phase 2 TEDOVA trial evaluating Tedopi, with or without p...
Whitehawk Therapeutics signs new option agreement for use of CPT113 linker-payload
22 May 2026 - Clinical-stage oncology therapeutics company Whitehawk Therapeutics Inc (Nasdaq:WHWK) announced on Thursday that it has signed a new option agreement with Hangzhou DAC for access to CPT1...
4basebio secures clinical supply agreement for Phase II immunotherapy trial
20 May 2026 - Cambridge-based biotechnology company 4basebio PLC (AIM: 4BB) disclosed on Wednesday that it has signed a Clinical Supply Agreement with an unnamed cancer immunotherapy developer to prov...
FDA approves MEKanistic Therapeutics' IND for MTX-531
20 May 2026 - Biotechnology company MEKanistic Therapeutics announced on Tuesday that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug application for MTX-531, its le...
Matter Bio submits first IND application for Lm-LLO-TT
20 May 2026 - Biotechnology company Matter Bio announced on Tuesday the submission of its first Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for Lm-LLO-TT fo...